Corxel Pharmaceuticals closed a $287 million financing to advance its oral GLP‑1 candidate into phase 2/3 studies. The company licensed the oral agent from China‑based Vincentage in 2024 and is positioning the pill as a tenant in the competitive obesity and metabolic market dominated by injectable GLP‑1s. The capital raise aims to fund late‑stage clinical work and global development activities.